We are live on ! Find out more
THRD

Third Harmonic Bio

Delisted

THRD was delisted on the 30th of July, 2025.

48 hedge funds and large institutions have $173M invested in Third Harmonic Bio in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

667% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 3

16% more capital invested

Capital invested by funds: $150M → $173M (+$23.7M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.79% less ownership

Funds ownership: 90.14%89.35% (-0.79%)

2% less funds holding

Funds holding: 4948 (-1)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Holders
48
Holders Change
-1
Holders Change %
-2.04%
% of All Funds
0.75%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
23
Reduced
3
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$52.5M
O
2
OrbiMed
New York
$27.8M
BI
3
BVF Inc
California
$21M
GA
4
General Atlantic
New York
$14.2M
SCM
5
Stonepine Capital Management
Oregon
$13.4M -$1.61M -338,846 -11%
EC
6
EcoR1 Capital
California
$10M +$1.36M +286,658 +16%
TCM
7
Tang Capital Management
California
$8.66M
BlackRock
8
BlackRock
New York
$5.17M +$1.66M +348,845 +48%
CC
9
Commodore Capital
New York
$4.78M
Vanguard Group
10
Vanguard Group
Pennsylvania
$3.7M +$104K +21,897 +3%
BCLSI
11
Bain Capital Life Sciences Investors
Massachusetts
$3.08M
BC
12
Boxer Capital
California
$2.74M
Geode Capital Management
13
Geode Capital Management
Massachusetts
$1.52M +$345K +72,483 +30%
State Street
14
State Street
Massachusetts
$1.27M +$219K +46,073 +21%
Northern Trust
15
Northern Trust
Illinois
$697K +$203K +42,724 +42%
Morgan Stanley
16
Morgan Stanley
New York
$640K +$219K +45,927 +53%
Charles Schwab
17
Charles Schwab
California
$497K +$78.5K +16,492 +19%
BCM
18
Bridgeway Capital Management
Texas
$429K +$143K +30,000 +51%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$257K +$80.5K +16,916 +46%
N
20
Nuveen
North Carolina
$129K +$44.5K +9,348 +53%
Bank of America
21
Bank of America
North Carolina
$97.9K +$58.4K +12,265 +152%
RhumbLine Advisers
22
RhumbLine Advisers
Massachusetts
$80.7K +$23.3K +4,885 +41%
Goldman Sachs
23
Goldman Sachs
New York
$79.2K +$78.4K +16,460 New
PCM
24
Prelude Capital Management
New York
$76.2K +$75.4K +15,842 New
JP Morgan Chase
25
JP Morgan Chase
New York
$74.7K +$1.23K +258 +2%

THRD Hedge Fund Activity: Q2 2023 in Review

48 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q2 2023, worth a combined $173M — up 16% from $150M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of THRD and 8 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 23 added.

The largest buyer was BlackRock, adding an estimated $1.66M. The largest seller was RTW Investments, exiting entirely with an estimated $2.2M sold.

  • 48 institutional investors held Third Harmonic Bio (THRD) as of Q2 2023, down from 49 in Q1 2023.
  • Funds reported $173M of Third Harmonic Bio stock for Q2 2023, up 16% quarter-over-quarter.
  • 8 funds opened new Third Harmonic Bio positions in Q2 2023 and 9 closed out, a net change of -1 holder.
  • The largest Third Harmonic Bio buyer in Q2 2023 was BlackRock, an estimated $1.66M added.
  • The largest Third Harmonic Bio seller in Q2 2023 was RTW Investments, an estimated $2.2M sold.

Based on aggregated 13F filings for Q2 2023.